You are analyzing prescribing quality indicators for patients with multimorbidity in your practice. You identify that 22% of patients aged 75+ taking ≥10 medications have not had a structured medication review in the past 12 months. The practice decides to implement a systematic approach to medication reviews. According to NHS England guidance on structured medication reviews, which patients should be prioritized for review FIRST?
Q102
A 75-year-old man with Parkinson's disease, type 2 diabetes, hypertension, and depression takes 11 medications including co-careldopa 25/100 TDS, ropinirole PR 8mg daily, metformin 1g BD, gliclazide 80mg BD, amlodipine 10mg daily, ramipril 5mg daily, atorvastatin 20mg daily, citalopram 20mg daily, and senna two tablets at night. He reports postural dizziness and a fall last week. Lying BP 142/86 mmHg, standing BP 106/68 mmHg (after 3 minutes). Which medication adjustment should be prioritized based on his orthostatic hypotension?
Q103
During a practice audit of patients over 75 years taking 10 or more medications, you identify a 76-year-old man taking aspirin 75mg, clopidogrel 75mg, lansoprazole 30mg, atorvastatin 80mg, bisoprolol 10mg, ramipril 10mg, furosemide 40mg, spironolactone 25mg, allopurinol 300mg, and paracetamol 1g QDS for chronic knee pain. He had a drug-eluting stent inserted 16 months ago. His recent eGFR is 48 ml/min/1.73m², potassium 4.9 mmol/L. What is the MOST appropriate medication change to consider at this review?
Q104
A 70-year-old woman with rheumatoid arthritis, osteoporosis, hypertension, and type 2 diabetes attends for her annual medication review. Her medications include: methotrexate 15mg weekly, folic acid 5mg weekly, hydroxychloroquine 200mg BD, prednisolone 5mg daily, alendronic acid 70mg weekly, amlodipine 5mg daily, ramipril 10mg daily, and metformin 1g BD. She mentions she takes all her tablets together on Sunday morning for convenience. What is the MOST important prescribing issue to address?
Q105
You are conducting a structured medication review for a 73-year-old man with COPD, ischaemic heart disease, hypertension, benign prostatic hyperplasia, and chronic back pain. His medications include: aspirin 75mg, atorvastatin 80mg, bisoprolol 2.5mg, ramipril 5mg, tiotropium inhaler, salbutamol inhaler, tamsulosin 400mcg, co-codamol 30/500 QDS, and diazepam 5mg at night (prescribed 18 months ago for sleep). He reports daytime drowsiness and two recent falls. Applying STOPP/START criteria, which medication represents the HIGHEST priority for discontinuation?
Q106
A 79-year-old woman with heart failure (LVEF 40%), atrial fibrillation, type 2 diabetes, and osteoporosis takes 12 medications including bisoprolol 5mg daily, furosemide 40mg daily, apixaban 5mg BD, metformin 500mg BD, alendronic acid 70mg weekly, and omeprazole 20mg daily. She has been taking omeprazole for 6 years, initially prescribed for dyspepsia. She has had no dyspeptic symptoms for over 3 years. Recent bone density scan shows ongoing osteoporosis. What is the MOST appropriate action regarding her proton pump inhibitor?
Q107
A 66-year-old man attends for a medication review. He has been taking 14 regular medications for various conditions including hypertension, type 2 diabetes, hyperlipidaemia, GORD, benign prostatic hyperplasia, and insomnia. He reports that managing his medications has become burdensome and he sometimes forgets doses. His recent HbA1c is 51 mmol/mol, blood pressure 138/82 mmHg, and lipid profile shows total cholesterol 4.2 mmol/L. When applying deprescribing principles in this scenario, what is the MOST important first step?
Q108
A 68-year-old woman with multiple sclerosis, depression, type 2 diabetes, and hypertension attends with her husband. She has recently developed urinary incontinence and recurrent urinary tract infections. Her current medications include glatiramer acetate, sertraline 100mg daily, metformin 500mg BD, lisinopril 10mg daily, and oxybutynin 5mg TDS which was started by urology 2 months ago. She reports worsening memory problems and constipation since starting the new medication. What is the BEST interpretation of this clinical scenario?
Q109
You are reviewing a 74-year-old man with type 2 diabetes, ischaemic heart disease, heart failure (LVEF 38%), and hypertension who takes 9 medications including aspirin, atorvastatin, bisoprolol, ramipril, furosemide, metformin, gliclazide, and omeprazole. Recent blood tests show eGFR 38 ml/min/1.73m², HbA1c 64 mmol/mol, and potassium 5.2 mmol/L. Understanding the principles of managing multimorbidity, which aspect of his care requires MOST urgent review?
Q110
A 71-year-old man with type 2 diabetes, COPD, chronic kidney disease stage 3a (eGFR 52 ml/min/1.73m²), and hypertension attends for review. His HbA1c is 58 mmol/mol on metformin 1g BD. His blood pressure is consistently 148/88 mmHg on amlodipine 10mg daily. He also takes tiotropium and salbutamol inhalers. His main concern is breathlessness limiting his ability to garden. What is the MOST appropriate approach to managing his competing health priorities?
Chronic Disease Management UK Medical PG Practice Questions and MCQs
Question 101: You are analyzing prescribing quality indicators for patients with multimorbidity in your practice. You identify that 22% of patients aged 75+ taking ≥10 medications have not had a structured medication review in the past 12 months. The practice decides to implement a systematic approach to medication reviews. According to NHS England guidance on structured medication reviews, which patients should be prioritized for review FIRST?
A. All patients over 80 years regardless of medication number or clinical stability
B. Patients prescribed medications from the highest risk medication categories
C. Patients with the highest number of medications regardless of other factors
D. Patients who have had recent hospital admissions or changes in clinical condition (Correct Answer)
E. Patients with poorest adherence as identified by prescription collection data
Explanation: ***Patients who have had recent hospital admissions or changes in clinical condition***- According to **NHS England guidance** and the **Network Contract DES**, patients with recent **hospital admissions** or acute clinical changes are the highest priority for **Structured Medication Reviews (SMRs)**.- These patients are at the greatest risk of **medication-related harm**, drug interactions, and inappropriate prescribing following transitions of care or clinical deterioration.*All patients over 80 years regardless of medication number or clinical stability*- **Age alone** is not the primary determinant for prioritization in the SMR framework; focus is on **clinical vulnerability** and complexity.- Prioritizing solely by age may overlook younger, high-risk patients with **multimorbidity** or frequent hospital attendances.*Patients prescribed medications from the highest risk medication categories*- While patients on **high-risk drugs** like anticoagulants or NSAIDs require monitoring, they are often reviewed periodically through specific **safety audits**.- High-risk medication use is a key trigger for an SMR, but a **recent hospital discharge** represents a more immediate clinical priority for review.*Patients with the highest number of medications regardless of other factors*- While **polypharmacy** (e.g., taking ≥10 medications) is a criterion for SMR eligibility, it does not automatically define the **immediate priority**.- A stable patient on many medications may be at lower immediate risk than a patient on fewer medications who has just experienced a **major health change**.*Patients with poorest adherence as identified by prescription collection data*- Addressing **non-adherence** is a vital component of a medication review, but it does not carry the same degree of **acute clinical risk** as recent hospitalization.- Poor adherence data should prompt an investigation into **patient barriers**, but systematic prioritization favors those with recent **clinical instability**.
Question 102: A 75-year-old man with Parkinson's disease, type 2 diabetes, hypertension, and depression takes 11 medications including co-careldopa 25/100 TDS, ropinirole PR 8mg daily, metformin 1g BD, gliclazide 80mg BD, amlodipine 10mg daily, ramipril 5mg daily, atorvastatin 20mg daily, citalopram 20mg daily, and senna two tablets at night. He reports postural dizziness and a fall last week. Lying BP 142/86 mmHg, standing BP 106/68 mmHg (after 3 minutes). Which medication adjustment should be prioritized based on his orthostatic hypotension?
A. Reduce ramipril dose as ACE inhibitors commonly cause postural hypotension
B. Stop amlodipine as calcium channel blockers cause vasodilation and hypotension
C. Review ropinirole dose as dopamine agonists frequently cause orthostatic hypotension (Correct Answer)
D. Discontinue senna as chronic laxative use can lead to fluid and electrolyte depletion
E. Reduce gliclazide dose as hypoglycaemia may be contributing to dizziness
Explanation: ***Review ropinirole dose as dopamine agonists frequently cause orthostatic hypotension***
- **Dopamine agonists** like **ropinirole** are strongly associated with **orthostatic hypotension** due to peripheral vasodilation and interference with autonomic cardiovascular reflexes.
- In patients with **Parkinson’s disease**, it is standard practice to prioritize adjusting **dopaminergic agents** over life-saving antihypertensives when the patient remains hypertensive while supine (142/86 mmHg).
*Reduce ramipril dose as ACE inhibitors commonly cause postural hypotension*
- While **ACE inhibitors** can contribute to hypotension, the patient's **lying BP** is 142/86 mmHg, suggesting that his hypertension is not currently over-controlled.
- Withdrawing **ramipril** may lead to inadequate **cardiovascular protection** and worsening supine hypertension, a common complication in autonomic failure.
*Stop amlodipine as calcium channel blockers cause vasodilation and hypotension*
- **Amlodipine** causes peripheral vasodilation, but it is less likely than **ropinirole** to be the primary driver of a sharp 36 mmHg **systolic drop** upon standing.
- Discontinuing it would leave his **lying blood pressure** above the target range, increasing his long-term risk of stroke and target organ damage.
*Discontinue senna as chronic laxative use can lead to fluid and electrolyte depletion*
- While extreme **fluid depletion** can cause hypotension, there is no clinical evidence provided (such as tachycardia or dry mucous membranes) to suggest **senna** is causing hypovolemia.
- Constipation is a significant issue in **Parkinson’s disease**, and stopping laxatives might worsen patient comfort without fixing the autonomic drop.
*Reduce gliclazide dose as hypoglycaemia may be contributing to dizziness*
- **Hypoglycemia** typically presents with sweating, tremor, and confusion rather than a specific **postural drop** in blood pressure.
- Dizziness from low blood sugar is not specifically tied to the **act of standing** (orthostasis), which is the primary finding in this clinical examination.
Question 103: During a practice audit of patients over 75 years taking 10 or more medications, you identify a 76-year-old man taking aspirin 75mg, clopidogrel 75mg, lansoprazole 30mg, atorvastatin 80mg, bisoprolol 10mg, ramipril 10mg, furosemide 40mg, spironolactone 25mg, allopurinol 300mg, and paracetamol 1g QDS for chronic knee pain. He had a drug-eluting stent inserted 16 months ago. His recent eGFR is 48 ml/min/1.73m², potassium 4.9 mmol/L. What is the MOST appropriate medication change to consider at this review?
A. Stop spironolactone due to risk of hyperkalaemia with declining renal function
B. Discontinue clopidogrel as dual antiplatelet therapy is no longer required (Correct Answer)
C. Reduce allopurinol dose to 200mg daily due to renal impairment
D. Stop lansoprazole as indication for gastroprotection will cease with clopidogrel
E. Replace paracetamol with codeine for better pain control
Explanation: ***Discontinue clopidogrel as dual antiplatelet therapy is no longer required***
- **Dual antiplatelet therapy (DAPT)** with aspirin and clopidogrel after drug-eluting stent (DES) insertion is typically recommended for **6-12 months**; at 16 months, the risk of stent thrombosis is low, and the **bleeding risk** outweighs the benefit.
- Continuing **aspirin monotherapy** is sufficient for long-term secondary prevention, which reduces **polypharmacy** and the patient's overall bleeding risk.
*Stop spironolactone due to risk of hyperkalaemia with declining renal function*
- The patient's potassium level of **4.9 mmol/L** is within the normal range, and spironolactone offers significant **mortality benefits** in conditions like heart failure.
- While an **eGFR of 48 ml/min/1.73m²** necessitates careful monitoring, stopping spironolactone is only warranted if potassium levels consistently exceed **5.5 mmol/L** or renal function significantly deteriorates.
*Reduce allopurinol dose to 200mg daily due to renal impairment*
- Allopurinol 300mg daily is generally considered appropriate for patients with an **eGFR above 30 ml/min/1.73m²**.
- Dose reduction is primarily recommended when the eGFR falls below **30 ml/min/1.73m²** to minimize the risk of **allopurinol hypersensitivity syndrome**.
*Stop lansoprazole as indication for gastroprotection will cease with clopidogrel*
- Even after discontinuing clopidogrel, the patient remains on **aspirin**, which itself carries a risk of **gastrointestinal bleeding**, especially in elderly individuals.
- The patient's age (76 years) is an independent risk factor for upper GI bleeding, suggesting a continued need for **gastroprotection**, or at least a thorough review of the ongoing indication rather than immediate cessation.
*Replace paracetamol with codeine for better pain control*
- Introducing **opioids** like codeine in an elderly patient on multiple medications increases the risk of adverse effects such as **falls, constipation, confusion, and respiratory depression**.
- Given the patient's **renal impairment**, active metabolites of codeine can accumulate, leading to **toxicity**, making paracetamol a safer choice for chronic pain management.
Question 104: A 70-year-old woman with rheumatoid arthritis, osteoporosis, hypertension, and type 2 diabetes attends for her annual medication review. Her medications include: methotrexate 15mg weekly, folic acid 5mg weekly, hydroxychloroquine 200mg BD, prednisolone 5mg daily, alendronic acid 70mg weekly, amlodipine 5mg daily, ramipril 10mg daily, and metformin 1g BD. She mentions she takes all her tablets together on Sunday morning for convenience. What is the MOST important prescribing issue to address?
A. Methotrexate and folic acid should be taken on different days
B. Alendronic acid must be taken separately on an empty stomach before other medications (Correct Answer)
C. Prednisolone should be taken in the morning with food, not as a single weekly dose
D. Hydroxychloroquine should be taken with food to reduce gastrointestinal side effects
E. Ramipril dose should be split to twice daily for better blood pressure control
Explanation: ***Alendronic acid must be taken separately on an empty stomach before other medications***- **Alendronic acid** has extremely poor bioavailability and must be taken with plain water on an **empty stomach**, at least 30 minutes before any food or other medications, to ensure absorption.- Taking it with other tablets and food (as the patient does on Sunday) essentially renders the medication ineffective, increasing the risk of **osteoporotic fractures** and potentially causing **oesophageal irritation**.*Methotrexate and folic acid should be taken on different days*- While **folic acid** is typically taken at least 24 hours after **methotrexate** to reduce gastrointestinal and mucosal side effects, this is a management preference rather than a strict contraindication that negates drug efficacy.- The critical failure of **bisphosphonate** absorption in this patient’s routine takes clinical priority over the precise timing of folate supplementation, making it the most important issue.*Prednisolone should be taken in the morning with food, not as a single weekly dose*- The patient is taking **prednisolone** daily, not weekly; the prompt indicates she takes *all her tablets together on Sunday morning* for convenience, which includes her daily prednisolone. However, the critical issue is the complete loss of efficacy for alendronic acid due to improper administration.- While **prednisolone** should ideally be taken daily in the morning with food to mimic **circadian cortisol** rhythms and reduce GI upset, improper bisphosphonate administration represents a more immediate and severe treatment failure.*Hydroxychloroquine should be taken with food to reduce gastrointestinal side effects*- **Hydroxychloroquine** is indeed better tolerated when taken with food to minimize **GI upset**, but it does not have the strict fasting requirements or severe bioavailability issues of bisphosphonates.- Failure to take it with food may cause discomfort but does not negate the drug's therapeutic efficacy in **rheumatoid arthritis** or pose the same immediate risk of fracture due to complete drug failure.*Ramipril dose should be split to twice daily for better blood pressure control*- **Ramipril** is an ACE inhibitor that is effectively dosed **once daily** due to its long half-life and duration of action, ensuring adequate blood pressure control throughout the 24-hour period.- Splitting the dose is not standard practice for **hypertension** management and does not address the immediate safety and efficacy concerns of the alendronic acid.
Question 105: You are conducting a structured medication review for a 73-year-old man with COPD, ischaemic heart disease, hypertension, benign prostatic hyperplasia, and chronic back pain. His medications include: aspirin 75mg, atorvastatin 80mg, bisoprolol 2.5mg, ramipril 5mg, tiotropium inhaler, salbutamol inhaler, tamsulosin 400mcg, co-codamol 30/500 QDS, and diazepam 5mg at night (prescribed 18 months ago for sleep). He reports daytime drowsiness and two recent falls. Applying STOPP/START criteria, which medication represents the HIGHEST priority for discontinuation?
A. Co-codamol due to risk of constipation and cognitive impairment
B. Diazepam due to long-term benzodiazepine use increasing fall risk (Correct Answer)
C. Bisoprolol due to potential exacerbation of COPD symptoms
D. Tamsulosin due to hypotensive effects contributing to falls
E. Aspirin due to lack of clear indication in stable ischaemic heart disease
Explanation: ***Diazepam due to long-term benzodiazepine use increasing fall risk***
- According to **STOPP criteria**, long-term use (>4 weeks) of **benzodiazepines** in older adults is inappropriate due to the high risk of **sedation**, **cognitive impairment**, and **falls**.
- This patient’s **daytime drowsiness** and **recent falls** are classic complications of long-acting drugs like diazepam, making its gradual withdrawal the highest priority.
*Co-codamol due to risk of constipation and cognitive impairment*
- While opioids like **codeine** contribute to sedation and falls, they may be necessary for managing his **chronic back pain**, making discontinuation a secondary consideration.
- The priority is lower compared to the benzodiazepine, which has no valid long-term indication for sleep in this clinical context.
*Bisoprolol due to potential exacerbation of COPD symptoms*
- **Bisoprolol** is a **cardioselective beta-blocker** and is generally safe to use in **COPD** patients, especially when required for **ischaemic heart disease**.
- The benefits for his cardiac health currently outweigh the low risk of bronchospasm at this low dose (2.5mg).
*Tamsulosin due to hypotensive effects contributing to falls*
- **Tamsulosin** is an alpha-blocker that can lead to **orthostatic hypotension**, but it is essential for managing symptoms of **benign prostatic hyperplasia (BPH)**.
- It should be reviewed if falls persist after withdrawing sedatives, but it is not the primary culprit for his current **daytime drowsiness**.
*Aspirin due to lack of clear indication in stable ischaemic heart disease*
- **Aspirin** is indicated for the **secondary prevention** of cardiovascular events in patients with documented **ischaemic heart disease**.
- Discontinuing it would increase the risk of myocardial infarction and does not address the patient's immediate problem of falls and drowsiness.
Question 106: A 79-year-old woman with heart failure (LVEF 40%), atrial fibrillation, type 2 diabetes, and osteoporosis takes 12 medications including bisoprolol 5mg daily, furosemide 40mg daily, apixaban 5mg BD, metformin 500mg BD, alendronic acid 70mg weekly, and omeprazole 20mg daily. She has been taking omeprazole for 6 years, initially prescribed for dyspepsia. She has had no dyspeptic symptoms for over 3 years. Recent bone density scan shows ongoing osteoporosis. What is the MOST appropriate action regarding her proton pump inhibitor?
A. Continue omeprazole as it provides gastroprotection for her multiple medications
B. Switch to ranitidine as this has fewer interactions with her other medications
C. Attempt to stop omeprazole with a trial period off treatment (Correct Answer)
D. Reduce omeprazole to alternate days before considering complete discontinuation
E. Continue omeprazole but add calcium supplementation to mitigate bone effects
Explanation: ***Attempt to stop omeprazole with a trial period off treatment***
- Long-term **Proton Pump Inhibitor (PPI)** use without a clear indication significantly increases the risk of **fractures** and exacerbates **osteoporosis**, which is highly relevant given this patient's ongoing bone density issues despite alendronate.
- As the patient has been completely asymptomatic for 3 years and lacks high-risk indications for ongoing gastroprotection (e.g., concurrent **NSAID** use, dual antiplatelet therapy, or a history of upper GI bleed), **deprescribing** via a trial cessation is the most appropriate clinical step.
*Continue omeprazole as it provides gastroprotection for her multiple medications*
- While the patient is on numerous medications, none of them (such as **Apixaban**, **Bisoprolol**, or **Metformin**) strictly necessitate long-term PPI gastroprotection in the absence of a history of peptic ulcers or current use of gastrotoxic drugs like NSAIDs.
- Routine, indefinite use of PPIs solely for "polypharmacy" is not recommended and contributes to **medication-related harm** and increased pill burden in the elderly population.
*Switch to ranitidine as this has fewer interactions with her other medications*
- **H2 antagonists** like ranitidine are not indicated for an asymptomatic patient with no active dyspeptic symptoms, and ranitidine specifically has faced global **regulatory withdrawals** due to potential N-nitrosodimethylamine (NDMA) impurities.
- Switching to another acid-suppressant does not address the primary goal of reducing **unnecessary medications** (deprescribing) in an elderly patient who has no ongoing indication for acid suppression.
*Reduce omeprazole to alternate days before considering complete discontinuation*
- While dose tapering can sometimes be used to mitigate **rebound acid hypersecretion** after long-term PPI use, for a patient who has been entirely asymptomatic for 3 years, a direct trial off treatment is the most appropriate and efficient initial step for deprescribing.
- Alternate-day dosing is often less effective for gradual withdrawal than a consistent **"step-down"** approach (e.g., reducing to a lower daily dose) if symptoms were actually present, which they are not in this case.
*Continue omeprazole but add calcium supplementation to mitigate bone effects*
- Adding more pills (e.g., calcium supplementation) to an already extensive medication list (12 drugs) increases **polypharmacy**, **pill burden**, and the risk of further drug interactions or non-adherence.
- PPIs can specifically impair the **absorption of calcium carbonate** by reducing gastric acid, making this approach potentially ineffective in fully mitigating the **osteoporosis risk** compared to simply stopping the unnecessary PPI.
Question 107: A 66-year-old man attends for a medication review. He has been taking 14 regular medications for various conditions including hypertension, type 2 diabetes, hyperlipidaemia, GORD, benign prostatic hyperplasia, and insomnia. He reports that managing his medications has become burdensome and he sometimes forgets doses. His recent HbA1c is 51 mmol/mol, blood pressure 138/82 mmHg, and lipid profile shows total cholesterol 4.2 mmol/L. When applying deprescribing principles in this scenario, what is the MOST important first step?
A. Discontinue the medication with the highest risk of adverse effects immediately
B. Explore the patient's understanding of his medications and his goals of care (Correct Answer)
C. Calculate his QRISK3 score to determine if lipid-lowering therapy can be reduced
D. Review each medication against STOPP/START criteria systematically
E. Stop medications for conditions where targets are already achieved
Explanation: ***Explore the patient's understanding of his medications and his goals of care***
- The first and most critical step in **deprescribing** is engaging in **shared decision-making** to align medical interventions with the patient's values and priorities.
- Understanding the patient's **treatment burden** and goals ensures that any changes to the regimen are sustainable and respect the patient's **quality of life**.
*Discontinue the medication with the highest risk of adverse effects immediately*
- Stopping medications abruptly without a **structured plan** or patient consultation can lead to **rebound symptoms** or withdrawal syndromes.
- Identifying high-risk drugs is part of the clinical review, but it should not precede the establishment of **goals of care**.
*Calculate his QRISK3 score to determine if lipid-lowering therapy can be reduced*
- While **risk assessment tools** are useful for evaluating the necessity of primary prevention, they represent a technical step rather than the **initial holistic approach**.
- A score alone does not address the patient's primary complaint of **medication burden** and forgetfulness.
*Review each medication against STOPP/START criteria systematically*
- **STOPP/START criteria** are evidence-based tools used to identify **potentially inappropriate medications**, but they are supplementary to the clinical conversation.
- These criteria provide a framework for the review process but should be applied only after the patient’s **preferences and context** have been established.
*Stop medications for conditions where targets are already achieved*
- Meeting clinical targets (like **HbA1c** or **Blood Pressure**) often means the medication is working effectively, and stopping them could lead to loss of **disease control**.
- **Deprescribing** is about assessing the ongoing **risk-benefit ratio** for the individual, not simply removing drugs once a numerical target is reached.
Question 108: A 68-year-old woman with multiple sclerosis, depression, type 2 diabetes, and hypertension attends with her husband. She has recently developed urinary incontinence and recurrent urinary tract infections. Her current medications include glatiramer acetate, sertraline 100mg daily, metformin 500mg BD, lisinopril 10mg daily, and oxybutynin 5mg TDS which was started by urology 2 months ago. She reports worsening memory problems and constipation since starting the new medication. What is the BEST interpretation of this clinical scenario?
A. Her multiple sclerosis is progressing and causing cognitive decline and autonomic dysfunction
B. She is experiencing anticholinergic adverse effects from oxybutynin (Correct Answer)
C. Her depression is inadequately controlled leading to cognitive symptoms
D. She has developed a dementia syndrome requiring specialist assessment
E. The urinary symptoms and cognitive decline suggest a new neurological event
Explanation: ***She is experiencing anticholinergic adverse effects from oxybutynin***- The temporal relationship between starting **oxybutynin** and the onset of **worsening memory problems** and **constipation** strongly indicates an adverse drug effect in this elderly patient.- **Oxybutynin** is an **anticholinergic medication** known to cause cognitive impairment, constipation, and urinary retention (which can lead to recurrent UTIs), particularly in older adults due to its **CNS penetration** and high anticholinergic burden.*Her multiple sclerosis is progressing and causing cognitive decline and autonomic dysfunction*- While **MS progression** can lead to cognitive and autonomic symptoms, the *acute onset* directly following the initiation of a new medication makes this less likely to be the *best* primary interpretation.- The specific cluster of **memory issues**, **constipation**, and altered bladder function aligning with known anticholinergic side effects points away from solely MS progression.*Her depression is inadequately controlled leading to cognitive symptoms*- Although **depression** can cause cognitive symptoms (sometimes termed **pseudodementia**), it would not typically explain new physical symptoms like **constipation** appearing directly after starting a non-antidepressant medication.- The patient is already on **sertraline**, and the clear temporal link to oxybutynin strongly suggests a drug-related adverse effect rather than uncontrolled depression.*She has developed a dementia syndrome requiring specialist assessment*- A diagnosis of **dementia** requires chronic progression and, importantly, the exclusion of **reversible causes**, with medication-induced cognitive impairment being a key reversible factor.- The sudden onset of cognitive decline alongside other specific symptoms (constipation, urinary issues) after starting **oxybutynin** makes a primary dementia diagnosis less likely as the *initial* interpretation.*The urinary symptoms and cognitive decline suggest a new neurological event*- While a new **neurological event** such as a stroke or an MS relapse could cause sudden changes, the constellation of **memory impairment**, **constipation**, and urinary issues, all appearing after starting a known **anticholinergic drug**, makes an adverse drug reaction a more direct and probable explanation.- It is critical to first rule out **iatrogenic causes** (e.g., drug side effects) before considering a complex new neurological event, especially in an older patient on multiple medications.
Question 109: You are reviewing a 74-year-old man with type 2 diabetes, ischaemic heart disease, heart failure (LVEF 38%), and hypertension who takes 9 medications including aspirin, atorvastatin, bisoprolol, ramipril, furosemide, metformin, gliclazide, and omeprazole. Recent blood tests show eGFR 38 ml/min/1.73m², HbA1c 64 mmol/mol, and potassium 5.2 mmol/L. Understanding the principles of managing multimorbidity, which aspect of his care requires MOST urgent review?
A. His diabetes control as HbA1c is above target and may require intensification
B. His medication regimen in light of declining renal function and hyperkalaemia (Correct Answer)
C. His heart failure management as LVEF suggests suboptimal beta-blocker dosing
D. His cardiovascular risk as he may benefit from adding ezetimibe to his statin
E. His proton pump inhibitor use as long-term omeprazole may not be indicated
Explanation: ***His medication regimen in light of declining renal function and hyperkalaemia***
- The patient has **Stage 3b Chronic Kidney Disease (CKD)** with an eGFR of 38 ml/min/1.73m² and **hyperkalaemia** (potassium 5.2 mmol/L), which creates immediate safety risks regarding his current prescriptions.
- **Ramipril** can worsen hyperkalaemia and needs dose adjustment in CKD, while **Metformin** (risk of lactic acidosis) and **Gliclazide** (risk of hypoglycaemia) require urgent review in the context of impaired renal function.
*His diabetes control as HbA1c is above target and may require intensification*
- While an **HbA1c of 64 mmol/mol** is above the standard target, guidelines for older patients with multimorbidity prioritize safety and **individualized, less stringent glycemic targets** to prevent **hypoglycaemia**.
- Intensifying diabetes treatment now, especially with **gliclazide**, without addressing the **renal impairment** would significantly increase the risk of severe adverse events.
*His heart failure management as LVEF suggests suboptimal beta-blocker dosing*
- Optimizing **bisoprolol** for heart failure with reduced ejection fraction (HFrEF) is important for long-term outcomes but is not an acute safety concern requiring the *most urgent* review.
- Any dose adjustments to heart failure medications should be considered after stabilizing **renal function** and **electrolyte balance**.
*His cardiovascular risk as he may benefit from adding ezetimibe to his statin*
- Adding **ezetimibe** for secondary prevention of ischaemic heart disease is a chronic management step that does not take precedence over **acute metabolic derangements** and medication safety concerns.
- Managing **polypharmacy** and preventing immediate medication-related harm is more urgent in this patient than further adjusting lipid-lowering therapy.
*His proton pump inhibitor use as long-term omeprazole may not be indicated*
- **Deprescribing** non-essential medications like **omeprazole** is a good principle in reducing polypharmacy, but it is not as medically urgent as managing hyperkalaemia and reviewing medications posing direct risks in renal impairment.
- While PPIs have long-term considerations, the immediate risk posed by drugs like **Ramipril**, **Metformin**, and **Gliclazide** in the presence of **CKD** and **hyperkalaemia** is far greater.
Question 110: A 71-year-old man with type 2 diabetes, COPD, chronic kidney disease stage 3a (eGFR 52 ml/min/1.73m²), and hypertension attends for review. His HbA1c is 58 mmol/mol on metformin 1g BD. His blood pressure is consistently 148/88 mmHg on amlodipine 10mg daily. He also takes tiotropium and salbutamol inhalers. His main concern is breathlessness limiting his ability to garden. What is the MOST appropriate approach to managing his competing health priorities?
A. Intensify diabetes treatment to achieve HbA1c below 53 mmol/mol as per guidelines
B. Add an ACE inhibitor to improve blood pressure control and provide renal protection
C. Focus on optimising his COPD management as this is causing his main symptom (Correct Answer)
D. Arrange comprehensive geriatric assessment to address all conditions simultaneously
E. Refer to secondary care for specialist management of his complex multimorbidity
Explanation: ***Focus on optimising his COPD management as this is causing his main symptom***- In patients with **multimorbidity**, clinical guidelines suggest prioritizing the **patient's main concern**, which in this case is breathlessness limiting his quality of life.- Optimizing **COPD** (e.g., checking inhaler technique or upgrading to LAMA/LABA) directly addresses his functional impairment and aligns with **patient-centered care** as per **NICE NG56**.*Intensify diabetes treatment to achieve HbA1c below 53 mmol/mol as per guidelines*- Rigidly following **disease-specific guidelines** for HbA1c in elderly patients with multimorbidity can increase the risk of **hypoglycemia** and polypharmacy.- His current HbA1c of 58 mmol/mol is reasonable given his age and comorbidities; it is not the cause of his acute **functional limitation**.*Add an ACE inhibitor to improve blood pressure control and provide renal protection*- While an **ACE inhibitor** is indicated for **CKD** and hypertension, it does not address the patient's primary complaint of **breathlessness**.- Adding more medication should be balanced against the patient's **treatment burden** and prioritized after symptomatic relief is achieved.*Arrange comprehensive geriatric assessment to address all conditions simultaneously*- While a **Comprehensive Geriatric Assessment (CGA)** is useful for frailty, clinical management should first address the **symptomatic priority** identified during the consultation.- A CGA may be overly complex for a focused review of a patient whose primary barrier to activity is a specific **respiratory symptom**.*Refer to secondary care for specialist management of his complex multimorbidity*- Most patients with stable **multimorbidity** can be managed effectively in **primary care** by prioritizing concerns and coordinating treatment.- Referral should be reserved for specific diagnostic uncertainty or **treatment-resistant symptoms** rather than general complexity.
